Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine clesrovimab-cfor (Enflonsia) for preventing respiratory syncytial virus (RSV) in ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns, Merck announced.Merck said it plans to make the ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus. Skip to content. Main Navigation. Search. Search for: Local Weather ...

US FDA approves Merck's RSV antibody for infants. ... The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during ...

US FDA approves Merck's RSV antibody for infants. ... The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during ...

The Food and Drug Administration on Monday approved Merck's shot designed to protect ... in the market are waiting for a meeting of outside vaccine advisors to the Centers for Disease Control ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Merck said in a release that it expects orders ... All of the companies in the market are waiting for a meeting of outside vaccine advisors to the Centers for Disease Control and Prevention ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus. Skip to content. Main Navigation. Search. Search for: Local NBC4 Investigates ...